TITLE

Successful treatment of H. pylori negative gastric malt lymphoma with rituximab

AUTHOR(S)
Chaudhary, Nadeem; Mesiya, Sikandar A
PUB. DATE
September 2003
SOURCE
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS192
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article "Successful Treatment of H. Pylori Negative Gastric Malt Lymphoma with Rituximab" by Nadeem Chaudhary and Sikandar A. Mesiya is presented.
ACCESSION #
66954927

 

Related Articles

  • Systemic Therapy of Primary Cutaneous B-cell Lymphoma, Marginal Zone Type, with Rituximab, a Chimeric Anti-CD20 Monoclonal Antibody. Soda, R.; Costanzo, A.; Cantonetti, M.; Orlandi, A.; Bianchi, L.; Chimenti, S. // Acta Dermato-Venereologica;Jun/Jul2001, Vol. 81 Issue 3, p207 

    Focuses on systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with a chimeric anti-CD20 monoclonal antibody named rituximab. Condition of a patient affected with lymphoma; Characteristics of the antibody rituximab; Observation of regulation of CD20 antigen on neoplastic...

  • Antineoplastics/pirarubicin.  // Reactions Weekly;6/5/2010, Issue 1304, p10 

    The article describes the case of a 60-year-old woman who experienced severe and persistent panhypogammaglobulinaemia following completion of rituximab combined chemotherapy for follicular lymphoma.

  • Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Witzens-Harig, Mathias; Foá, Robin; Rocco, Alice; Hazel, Guy; Chamone, Dalton; Rowe, Jacob; Arcaini, Luca; Poddubnaya, Irina; Ho, Anthony; Ivanova, Valentina; Vranovsky, Andrej; Thurley, Dan; Oertel, Stephan // Annals of Hematology;Oct2014, Vol. 93 Issue 10, p1807 

    A correction to the article "Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study" that was published in the July 4, 2014 issue is presented.

  • Induction therapy benefited older patients with mantle cell lymphoma.  // Hem/Onc Today;9/10/2012, Vol. 13 Issue 17, p20 

    The article discusses research led by Hanneke C. Kluin-Nelemans of the University Medical Center Groningen in the Netherlands that shows that older patients with mantle cell lymphoma who responded to R-CHOP followed by maintenance therapy with rituximab almost doubled their remission duration.

  • After chemotherapy, maintenance rituximab prolonged PFS in indolent lymphoma.  // Hem/Onc Today;5/10/2009, Vol. 10 Issue 9, p31 

    The article discusses research being done on rituximab and lymphoma, referencing a study by H. Hochster et al published in a 2009 issue of the "Journal of Clinical Oncology."

  • Rituximab.  // Reactions Weekly;6/9/2012, Issue 1405, p32 

    The article describes the case of a 71-year-old man and a 89-year-old man with diffuse large B-cell lymphoma who developed acute tumour lysis syndrome after treatment with rituximab, and who subsequently died.

  • Non-Hodgkin Lymphoma.  // Current Medical Literature: Leukemia & Lymphoma;2010, Vol. 18 Issue 1, p20 

    This article reviews several articles on non-Hodgkin lymphoma, including "Phase I Study of the Humanized Anti-Cd40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's lymphoma," by R. Advani, "Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem...

  • Doubled chance of sustained remission in follicular lymphoma with rituximab maintenance.  // British Journal of Hospital Medicine (17508460);Jun2010, Vol. 71 Issue 6, p309 

    The article reports on the findings of a study which determined the capacity of rituximab to reduce the risk of disease progression on untreated patients with follicular lymphoma.

  • Re-treatment strategy challenges maintenance therapy for rituximab use in low-burden FL.  // Hem/Onc Today;12/25/2011, Vol. 12 Issue 24, p58 

    The article discusses the results of a study by Brad S. Kahl of the University of Wisconsin which suggests the challenge posed by re-treatment strategy to maintenance therapy for rituximab use in low-burden follicular lymphoma (FL).

  • FDA approves rituximab for advanced follicular lymphoma.  // Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p3 

    The article reports on the approval of the drug rituximab by the U.S. Food and Drug Administration (FDA) for the treatment for advanced follicular lymphoma.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics